These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 25124483

  • 1. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder: an update.
    Awudu GA, Besag FM.
    Drug Saf; 2014 Sep; 37(9):661-76. PubMed ID: 25124483
    [Abstract] [Full Text] [Related]

  • 2. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder.
    Stiefel G, Besag FM.
    Drug Saf; 2010 Oct 01; 33(10):821-42. PubMed ID: 20812768
    [Abstract] [Full Text] [Related]

  • 3. Cardiovascular Effects of Stimulant and Non-Stimulant Medication for Children and Adolescents with ADHD: A Systematic Review and Meta-Analysis of Trials of Methylphenidate, Amphetamines and Atomoxetine.
    Hennissen L, Bakker MJ, Banaschewski T, Carucci S, Coghill D, Danckaerts M, Dittmann RW, Hollis C, Kovshoff H, McCarthy S, Nagy P, Sonuga-Barke E, Wong IC, Zuddas A, Rosenthal E, Buitelaar JK, ADDUCE consortium.
    CNS Drugs; 2017 Mar 01; 31(3):199-215. PubMed ID: 28236285
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.
    Findling RL.
    Clin Ther; 2008 May 01; 30(5):942-57. PubMed ID: 18555941
    [Abstract] [Full Text] [Related]

  • 6. Sleep disturbances and ADHD medications.
    Rostain AL.
    Curr Psychiatry Rep; 2007 Oct 01; 9(5):399-400. PubMed ID: 17915079
    [No Abstract] [Full Text] [Related]

  • 7. ADHD update: new data on the risks of medication.
    Harv Ment Health Lett; 2006 Oct 01; 23(4):3-5. PubMed ID: 17183739
    [No Abstract] [Full Text] [Related]

  • 8. Treatment of adult ADHD and comorbid disorders.
    Young JL.
    CNS Spectr; 2006 Oct 01; 11(10 Suppl 11):10-2. PubMed ID: 17712918
    [No Abstract] [Full Text] [Related]

  • 9. [Cardiovascular risks and management during Attention Deficit Hyperactivity Disorder treatment with methylphenidate].
    Bange F, Le Heuzey MF, Acquaviva E, Delorme R, Mouren MC.
    Arch Pediatr; 2014 Jan 01; 21(1):108-12. PubMed ID: 24309201
    [Abstract] [Full Text] [Related]

  • 10. Cardiovascular measures in children and adolescents with attention-deficit/hyperactivity disorder who are new users of methylphenidate and atomoxetine.
    Arcieri R, Germinario EA, Bonati M, Masi G, Zuddas A, Vella S, Chiarotti F, Panei P, Italian Attention-Deficit/Hyperactivity Disorder Regional Reference Centers.
    J Child Adolesc Psychopharmacol; 2012 Dec 01; 22(6):423-431. PubMed ID: 23362511
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Long-acting medications for the treatment of hyperkinetic disorders - a systematic review and European treatment guidelines. Part 2: a quantitative evaluation of long-acting medications].
    Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Döpfner M, Faraone SV, Rothenberger A, Sergeant J, Steinhausen HC, Sonuga-Barke EJ, Taylor E.
    Z Kinder Jugendpsychiatr Psychother; 2008 Mar 01; 36(2):97-106; quiz 106-7. PubMed ID: 18622939
    [Abstract] [Full Text] [Related]

  • 15. Cardiovascular safety of stimulant medications for pediatric attention-deficit hyperactivity disorder.
    Silva RR, Skimming JW, Muniz R.
    Clin Pediatr (Phila); 2010 Sep 01; 49(9):840-51. PubMed ID: 20693523
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Current pharmacotherapy of attention deficit hyperactivity disorder.
    Reddy DS.
    Drugs Today (Barc); 2013 Oct 01; 49(10):647-65. PubMed ID: 24191257
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.